Target intelligence / Profile preview

ZNF606 antisense RNA 1 (ZNF606-AS1)

Target
ZNF606-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

ZNF606 antisense RNA 1 (ZNF606-AS1) is a long non-coding RNA gene expressed as an antisense transcript to the protein-coding ZNF606 gene. Antisense lncRNAs as a class are known to regulate gene expression via epigenetic, transcriptional, or post-transcriptional mechanisms, typically by recruiting chromatin modifiers, interacting with transcription factors, or stabilizing/destabilizing sense mRNAs[1][2][3]. ZNF606-AS1 itself is uncharacterized in the literature regarding its specific biological roles, disease relevance, druggability, or clinical application. Its molecular identity places it in the growing family of regulatory lncRNAs with emerging importance in gene regulation and, occasionally, human disease, although direct evidence for ZNF606-AS1 is absent. ZNF606-AS1 is a non-protein-coding RNA, not a classical therapeutic target. It belongs to the family of antisense lncRNAs, which regulate gene expression but are not yet themselves directly linked to specific biological functions, disease roles, or pharmacological interventions[2][3]. There are no interacting drugs, established biomarkers, or safety concerns. The gene is accurately named and classified, but its function remains unstudied.

Other names
ZNF606-AS1ZNF606 antisense RNA 1
02

Mechanism of action

Not applicable. As no drugs target ZNF606-AS1, mechanism of action is undetermined. In principle, antisense lncRNAs can be targeted by synthetic antisense oligonucleotides (ASOs) for knockdown or modulation[3]. This is a general class-based inference, not validated for ZNF606-AS1 specifically.

03

Biological functions

Epigenetic regulation (affecting DNA methylation and histone modification by influencing adjacent or overlapping protein-coding loci)Transcriptional modulation (regulation of gene expression via interaction with chromatin or recruitment of transcriptional regulators)Potential involvement in gene silencing or activation (based on general antisense lncRNA mechanisms)
04

Disease associations

UncharacterizedCancer (some antisense lncRNAs are involved in tumor progression or suppression)Other regulatory or epigenetic disorders (general potential, not specifically for ZNF606-AS1)
05

Safety considerations

None reported.
06

Interacting drugs

None known.
07

Biomarkers

None known.

Beyond the preview

Go deeper on ZNF606 antisense RNA 1 (ZNF606-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZNF606 antisense RNA 1 (ZNF606-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call